A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents
暂无分享,去创建一个
[1] C. Rudin,et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] John O'Quigley,et al. Continual Reassessment Method for Ordered Groups , 2003, Biometrics.
[3] Peter F Thall,et al. Simultaneously optimizing dose and schedule of a new cytotoxic agent , 2007, Clinical trials.
[4] Anastasia Ivanova,et al. Two‐Dimensional Dose Finding in Discrete Dose Space , 2005, Biometrics.
[5] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[6] A. Boddy,et al. Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations , 2005, British Journal of Cancer.
[7] Peter F Thall,et al. Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.
[8] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.
[9] A Kramar,et al. Continual reassessment methods in phase I trials of the combination of two drugs in oncology. , 1999, Statistics in medicine.
[10] Shyamal D Peddada,et al. Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.
[11] R L Plackett,et al. A comparison of two approaches to the construction of models for quantal responses to mixtures of drugs. , 1967, Biometrics.
[12] Christian P. Robert,et al. Monte Carlo Statistical Methods , 2005, Springer Texts in Statistics.
[13] Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer , 2006, British Journal of Cancer.
[14] W J Shih,et al. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. , 2001, Biostatistics.
[15] J O'Quigley,et al. Continual reassessment method: a likelihood approach. , 1996, Biometrics.
[16] A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies , 2005, British Journal of Cancer.
[17] R. Amato,et al. Phase I/II study of thalidomide in combination with interleukin‐2 in patients with metastatic renal cell carcinoma , 2006, Cancer.
[18] C. Ahn,et al. An evaluation of phase I cancer clinical trial designs , 1998 .
[19] Ying Yuan,et al. Sequential continual reassessment method for two‐dimensional dose finding , 2008, Statistics in medicine.